September 6, 2024 10:25 AM EDT
Financing
Startups

Bicara, Zenas out­line plans for $180M IPOs amid re­stored op­ti­mism for biotech de­buts

Kyle LaHucik

Senior Reporter

Bicara Ther­a­peu­tics and Zenas Bio­Phar­ma are now a step clos­er to kick­ing open a mi­ni-IPO win­dow for drug de­vel­op­ers this fall.

The star­tups out­lined plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

A service from the Financial Times